{
    "nctId": "NCT04836156",
    "briefTitle": "Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients",
    "officialTitle": "Neoadjuvant Therapy Study Guided by Drug Screening in Vitro Patient-derived Tumor-like Cell Clusters for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-negative Early Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "pathological complete response(pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* invasive breast cancer\n* HER2 negative\n* T2 or node positive\n* Eastern Cooperative Oncology Group(ECOG) 0-1\n\nExclusion Criteria:\n\n* stage IV\n* inflammatory breast cancer\n* Severe chronic disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}